pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 9·1 min read
save

Podcast discusses health insurance costs, whistleblower case, and potential FDA commissioner picks

Jul 9, 2026·read at STAT ↗RegulatoryNeutral

The Readout LOUD podcast episode explores why employer-provided family health insurance can be as expensive as a new car.

The hosts interview a whistleblower who challenged an insurance contractor over cost practices, highlighting concerns about transparency and pricing.

They also discuss the pool of candidates being considered for the next FDA commissioner, noting how leadership choices could affect upcoming regulatory policies.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Whistleblower takes on health insurance and FDA commissioner candidates”

read at STAT ↗
644 words · retrieved Jul 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
ASTRAZENECA2ELI LILLY COLILLY
drugs
Obesity4
topics
Obesity4Oncology

related stories

  • 6d agoSTAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and moreSTAT
  • Aug 20Chutes & Ladders—Neumora shuffles leadership ahead of INDFierce Biotech
  • Jul 24Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaBioPharma Dive
  • Jul 2STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and moreSTAT
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive